JP7235511B2 - 組換え型一本鎖ｆｖｉｉｉおよびその化学コンジュゲート - Google Patents

組換え型一本鎖ｆｖｉｉｉおよびその化学コンジュゲート Download PDF

Info

Publication number
JP7235511B2
JP7235511B2 JP2018567079A JP2018567079A JP7235511B2 JP 7235511 B2 JP7235511 B2 JP 7235511B2 JP 2018567079 A JP2018567079 A JP 2018567079A JP 2018567079 A JP2018567079 A JP 2018567079A JP 7235511 B2 JP7235511 B2 JP 7235511B2
Authority
JP
Japan
Prior art keywords
fviii
chain
factor viii
domain
blood coagulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018567079A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527541A (ja
Inventor
カン・クァンヨプ
イ・スンフン
オ・インジェ
オ・ミスク
リュ・ジェファン
チョ・ウィチョル
イ・ギナム
ヤン・ソナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GREEN CROSS CORP
Mogam Institute for Biomedical Research
Original Assignee
GREEN CROSS CORP
Mogam Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GREEN CROSS CORP, Mogam Institute for Biomedical Research filed Critical GREEN CROSS CORP
Publication of JP2019527541A publication Critical patent/JP2019527541A/ja
Priority to JP2021065146A priority Critical patent/JP2021118696A/ja
Application granted granted Critical
Publication of JP7235511B2 publication Critical patent/JP7235511B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2018567079A 2016-06-24 2017-06-23 組換え型一本鎖ｆｖｉｉｉおよびその化学コンジュゲート Active JP7235511B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021065146A JP2021118696A (ja) 2016-06-24 2021-04-07 組換え型一本鎖ｆｖｉｉｉおよびその化学コンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160079442 2016-06-24
KR10-2016-0079442 2016-06-24
PCT/KR2017/006633 WO2017222330A1 (fr) 2016-06-24 2017-06-23 Chaîne unique recombinante fviii et son conjugué chimique

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021065146A Division JP2021118696A (ja) 2016-06-24 2021-04-07 組換え型一本鎖ｆｖｉｉｉおよびその化学コンジュゲート

Publications (2)

Publication Number Publication Date
JP2019527541A JP2019527541A (ja) 2019-10-03
JP7235511B2 true JP7235511B2 (ja) 2023-03-08

Family

ID=60783975

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018567079A Active JP7235511B2 (ja) 2016-06-24 2017-06-23 組換え型一本鎖ｆｖｉｉｉおよびその化学コンジュゲート
JP2021065146A Pending JP2021118696A (ja) 2016-06-24 2021-04-07 組換え型一本鎖ｆｖｉｉｉおよびその化学コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021065146A Pending JP2021118696A (ja) 2016-06-24 2021-04-07 組換え型一本鎖ｆｖｉｉｉおよびその化学コンジュゲート

Country Status (6)

Country Link
US (1) US20230151078A1 (fr)
EP (1) EP3476860A4 (fr)
JP (2) JP7235511B2 (fr)
KR (1) KR102219859B1 (fr)
CN (1) CN109689683A (fr)
WO (1) WO2017222330A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
IL310997A (en) * 2021-08-23 2024-04-01 Bioverativ Therapeutics Inc Factor VIII gene optimization
WO2023092864A1 (fr) * 2021-11-25 2023-06-01 Sichuan Real&Best Biotech Co., Ltd. Facteur viii humain modifié ayant une capacité de sécrétion et une activité de coagulation améliorées

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009542225A (ja) 2006-06-30 2009-12-03 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・ミシガン 組換え法によりｆｖｉｉｉタンパク質を生産する方法
JP2011523663A (ja) 2008-06-04 2011-08-18 バイエル・ヘルスケア・エルエルシー フォン・ヴィレブランド病の処置のためのｆｖｉｉｉ変異タンパク質
JP2013519636A (ja) 2010-02-16 2013-05-30 ノヴォ ノルディスク アー／エス コンジュゲートｆｖｉｉｉバリアント
JP2014531910A (ja) 2011-10-18 2014-12-04 シーエスエル、リミテッド 再構成後の精製第ｖｉｉｉ因子の安定性を改善するための方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
ES2911435T3 (es) * 2003-02-26 2022-05-19 Nektar Therapeutics Conjugados de polímero-resto de Factor VIII
NO20210454A1 (no) * 2004-11-12 2007-06-27 Bayer Healthcare Llc Setedirigert modifikasjon av FVIII
US20080227691A1 (en) * 2005-04-01 2008-09-18 Novo Nordisk Health Care Ag Blood Coagulation FVIII Analogues
EP2183282B1 (fr) 2007-07-13 2015-03-11 Ventana Medical Systems, Inc. Anticorps spécifiques au domaine régulateur c-terminal de l'egfr et leur utilisation
KR101948337B1 (ko) 2010-11-05 2019-02-14 박스알타 인코퍼레이티드 증가된 특이 활성도를 갖는 항혈우병 인자 ｖｉｉｉ의 신규 변이체
MY201293A (en) * 2012-01-12 2024-02-15 Bioverativ Therapeutics Inc Chimeric factor viii polypeptides and uses thereof
US10023628B2 (en) * 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009542225A (ja) 2006-06-30 2009-12-03 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・ミシガン 組換え法によりｆｖｉｉｉタンパク質を生産する方法
JP2011523663A (ja) 2008-06-04 2011-08-18 バイエル・ヘルスケア・エルエルシー フォン・ヴィレブランド病の処置のためのｆｖｉｉｉ変異タンパク質
JP2013519636A (ja) 2010-02-16 2013-05-30 ノヴォ ノルディスク アー／エス コンジュゲートｆｖｉｉｉバリアント
JP2014531910A (ja) 2011-10-18 2014-12-04 シーエスエル、リミテッド 再構成後の精製第ｖｉｉｉ因子の安定性を改善するための方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ＭＩＡＯ Ｈ． Ｚ． ｅｔ ａｌ．， Ｂｌｏｏｄ， ２００４年， Ｖｏｌ．１０３ Ｎｏ．９， ｐ．３４１２－３４１９
ＳＡＥＮＫＯ Ｅ． Ｌ． ｅｔ ａｌ．，Ｊ． Ｂｉｏｌ． Ｃｈｅｍ．，１９９７年， Ｖｏｌ．２７２ Ｎｏ．２９， ｐ．１８００７－１８０１４

Also Published As

Publication number Publication date
JP2021118696A (ja) 2021-08-12
JP2019527541A (ja) 2019-10-03
CN109689683A (zh) 2019-04-26
US20230151078A1 (en) 2023-05-18
EP3476860A1 (fr) 2019-05-01
KR20190018013A (ko) 2019-02-20
EP3476860A4 (fr) 2020-01-22
KR102219859B1 (ko) 2021-02-25
WO2017222330A1 (fr) 2017-12-28

Similar Documents

Publication Publication Date Title
JP5832285B2 (ja) 延長されたインビボ半減期を有する第ｖｉｉｉ因子、フォン・ヴィレブランド因子又はそれらの複合体
ES2434035T3 (es) Conjugados de polímero-factor von Willebrand
US20180092966A1 (en) Covalent complex of von willebrand factor and factor viii, compositions, and uses relating thereto
JP6877469B2 (ja) Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用
JP2021118696A (ja) 組換え型一本鎖ｆｖｉｉｉおよびその化学コンジュゲート
US9597378B2 (en) Blood coagulation factor VII and VIIa derivatives, conjugates and complexes comprising the same, and use thereof
US11560436B2 (en) Anti-VWF D'D3 single-domain antibodies fuse to clotting factors
KR20170010895A (ko) 인자 ⅷ 및 폰 빌레브란트 인자 펩티드를 포함하는 조제
JP7252890B2 (ja) 血友病を処置するための切断型フォン・ヴィルブランド因子ポリペプチド
AU2013202564B2 (en) Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
US20230190881A1 (en) Subcutaneous administration of factor viii
JP2018529760A (ja) 長半減期凝固複合体と関連する方法及び組成物
EP3785726A1 (fr) Protéine de facteur viii à demi-vie prolongée
FVIII A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200716

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210407

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210407

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210415

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210420

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210604

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210608

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220111

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220412

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220920

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20220920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221216

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20230110

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20230207

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20230207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230224

R150 Certificate of patent or registration of utility model

Ref document number: 7235511

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150